ALNY

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Alnylam Pharmaceuticals Inc

NASDAQ | ALNY

434.23

USD

$0.00

(

0.00%

)

At Close (As of Nov 24, 2025)

$57.65B

Market Cap

1407.68

P/E Ratio

0.31

EPS

$495.55

52 Week High

$205.87

52 Week Low

HEALTHCARE

Sector

ALNY Chart

Recent Chart
Price Action

ALNY Technicals

Tags:

ALNY Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $1.9B
Total Revenue $2.2B
Cost Of Revenue $323M
Costof Goods And Services Sold $323M
Operating Income -$177M
Selling General And Administrative $976M
Research And Development $1.1B
Operating Expenses $2.1B
Investment Income Net -
Net Interest Income -$20M
Interest Income $122M
Interest Expense $142M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $57M
Income Before Tax -$377M
Income Tax Expense -$99M
Interest And Debt Expense -
Net Income From Continuing Operations -$278M
Comprehensive Income Net Of Tax -
Ebit -$236M
Ebitda -$179M
Net Income -$278M

Revenue & Profitability

Earnings Performance

ALNY Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $4.2B
Total Current Assets $3.3B
Cash And Cash Equivalents At Carrying Value $966M
Cash And Short Term Investments $966M
Inventory $79M
Current Net Receivables $405M
Total Non Current Assets $945M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $1.7B
Other Current Assets $117M
Other Non Current Assets -
Total Liabilities $4.2B
Total Current Liabilities $1.2B
Current Accounts Payable $88M
Deferred Revenue -
Current Debt -
Short Term Debt $155M
Total Non Current Liabilities $3B
Capital Lease Obligations $271M
Long Term Debt $1B
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $2.7B
Other Current Liabilities $887M
Other Non Current Liabilities $1.7B
Total Shareholder Equity $67M
Treasury Stock -
Retained Earnings -$7.3B
Common Stock $1.3M
Common Stock Shares Outstanding $128M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$8.3M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $57M
Capital Expenditures $34M
Change In Receivables -
Change In Inventory $14M
Profit Loss -
Cashflow From Investment -$117M
Cashflow From Financing $294M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$278M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $1.9B
Total Revenue $2.2B
Cost Of Revenue $323M
Costof Goods And Services Sold $323M
Operating Income -$177M
Selling General And Administrative $976M
Research And Development $1.1B
Operating Expenses $2.1B
Investment Income Net -
Net Interest Income -$20M
Interest Income $122M
Interest Expense $142M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $57M
Income Before Tax -$377M
Income Tax Expense -$99M
Interest And Debt Expense -
Net Income From Continuing Operations -$278M
Comprehensive Income Net Of Tax -
Ebit -$236M
Ebitda -$179M
Net Income -$278M

ALNY News

ALNY Profile

Alnylam Pharmaceuticals Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Alnylam Pharmaceuticals, Inc. is a pioneering biopharmaceutical company headquartered in Cambridge, Massachusetts, specializing in the development and commercialization of transformative RNA interference (RNAi) therapeutics aimed at addressing genetic diseases. The company boasts a robust pipeline of innovative RNAi-based therapies and has made significant strides in the market, including the successful launch of its first commercial product. With a steadfast commitment to scientific excellence and the advancement of medicine, Alnylam is positioned as a leader in the biopharmaceutical sector, striving to redefine treatment paradigms for both rare and prevalent diseases.

LPTX
+368.57%
$2.05
IVP
+33.33%
$0.16
INHD
-33.64%
$0.48
NVDA
+2.05%
$182.55
ENLV
+13.73%
$1.02
VHAI
0.00%
$0.00
ONDS
+29.47%
$8.72
PLUG
-1.01%
$1.96
INTC
+3.73%
$35.79
TWOH
-13.33%
$0.00
TSLA
+6.82%
$417.78
VSA
+3.29%
$0.18
AEHL
+109.09%
$2.53
BYND
+0.01%
$0.86
GRAB
+7.14%
$5.25
GOOGL
+6.31%
$318.58
ASST
+10.78%
$1.13
DVLT
-5.09%
$2.42
NVO
-5.58%
$44.97
BMNR
+19.61%
$31.10
KVUE
+0.72%
$16.76
KTTA
+45.33%
$0.42
AXDX
-61.36%
$0.03
SOFI
+8.77%
$27.40
AAPL
+1.63%
$275.92
NFLX
+2.55%
$106.97
T
-1.19%
$25.62
PFE
+0.71%
$25.22
OSCR
+22.32%
$16.49
GELS
+20.38%
$1.06
PLTR
+4.77%
$162.25
AMZN
+2.53%
$226.28
GOOG
+6.28%
$318.47
MARA
+11.32%
$11.21
F
+1.01%
$12.96
BAC
+0.71%
$51.93
AAL
+1.78%
$13.10
NIO
+3.04%
$5.75
ADAP
-15.14%
$0.05
NBIS
+10.37%
$91.90
WBD
-1.33%
$22.86
BITF
+14.81%
$2.79
AVGO
+11.09%
$377.96
AMD
+5.53%
$215.05
CJET
-33.15%
$1.27
BTBT
+9.56%
$2.29
DNN
+2.20%
$2.32
VZ
-2.47%
$40.21
CIFR
+18.09%
$16.71
SOND
-23.45%
$0.12
RGTI
+12.63%
$26.57
WMT
-1.17%
$104.08
PCG
+1.78%
$15.95
CHR
-15.80%
$0.04
RIVN
+1.36%
$14.86
IONQ
+12.10%
$46.76
RMBL
+60.50%
$3.21
KO
-0.53%
$72.56
LNW
-3.71%
$86.22
ABEV
+1.61%
$2.52
ADD
-25.47%
$0.05
CLSK
+17.98%
$11.48
WULF
+11.86%
$12.63
SNAP
-0.13%
$7.68
IREN
+14.74%
$48.49
BTG
+9.44%
$4.17
TLRY
+6.52%
$0.96
HPE
+2.75%
$21.08
SRM
+53.27%
$10.30
MSFT
+0.39%
$474.00
RIG
+3.34%
$4.02
ACHR
+3.62%
$7.44
MU
+7.98%
$223.93
PLTD
-4.69%
$7.31
GPUS
+12.38%
$0.28
AMCR
+1.67%
$8.50
NOK
+2.52%
$6.09
HOOD
+7.14%
$114.97
ORCL
+0.76%
$200.28
CRWV
+2.72%
$73.60
SLB
-1.32%
$35.71
OSRH
+15.48%
$0.64
QBTS
+13.22%
$23.11
DFLI
+4.90%
$0.78
VIVK
+10.13%
$0.14
WLGS
-5.57%
$0.04
MTSR
-0.35%
$70.50
ATON
-6.16%
$2.74
BMNU
+39.92%
$7.36
SMCI
+3.51%
$33.32
FLEX
+3.00%
$56.95
APLD
+12.80%
$23.79
WFC
+1.86%
$84.66
MRK
+2.70%
$100.40
CSCO
+0.18%
$76.24
BURU
+3.03%
$0.21
CAN
+5.55%
$0.96
HBAN
+0.18%
$15.91
AMZE
+21.15%
$0.30
VINE
+21.15%
$0.30
LPTX
+368.57%
$2.05
IVP
+33.33%
$0.16
INHD
-33.64%
$0.48
NVDA
+2.05%
$182.55
ENLV
+13.73%
$1.02
VHAI
0.00%
$0.00
ONDS
+29.47%
$8.72
PLUG
-1.01%
$1.96
INTC
+3.73%
$35.79
TWOH
-13.33%
$0.00
TSLA
+6.82%
$417.78
VSA
+3.29%
$0.18
AEHL
+109.09%
$2.53
BYND
+0.01%
$0.86
GRAB
+7.14%
$5.25
GOOGL
+6.31%
$318.58
ASST
+10.78%
$1.13
DVLT
-5.09%
$2.42
NVO
-5.58%
$44.97
BMNR
+19.61%
$31.10
KVUE
+0.72%
$16.76
KTTA
+45.33%
$0.42
AXDX
-61.36%
$0.03
SOFI
+8.77%
$27.40
AAPL
+1.63%
$275.92
NFLX
+2.55%
$106.97
T
-1.19%
$25.62
PFE
+0.71%
$25.22
OSCR
+22.32%
$16.49
GELS
+20.38%
$1.06
PLTR
+4.77%
$162.25
AMZN
+2.53%
$226.28
GOOG
+6.28%
$318.47
MARA
+11.32%
$11.21
F
+1.01%
$12.96
BAC
+0.71%
$51.93
AAL
+1.78%
$13.10
NIO
+3.04%
$5.75
ADAP
-15.14%
$0.05
NBIS
+10.37%
$91.90
WBD
-1.33%
$22.86
BITF
+14.81%
$2.79
AVGO
+11.09%
$377.96
AMD
+5.53%
$215.05
CJET
-33.15%
$1.27
BTBT
+9.56%
$2.29
DNN
+2.20%
$2.32
VZ
-2.47%
$40.21
CIFR
+18.09%
$16.71
SOND
-23.45%
$0.12
RGTI
+12.63%
$26.57
WMT
-1.17%
$104.08
PCG
+1.78%
$15.95
CHR
-15.80%
$0.04
RIVN
+1.36%
$14.86
IONQ
+12.10%
$46.76
RMBL
+60.50%
$3.21
KO
-0.53%
$72.56
LNW
-3.71%
$86.22
ABEV
+1.61%
$2.52
ADD
-25.47%
$0.05
CLSK
+17.98%
$11.48
WULF
+11.86%
$12.63
SNAP
-0.13%
$7.68
IREN
+14.74%
$48.49
BTG
+9.44%
$4.17
TLRY
+6.52%
$0.96
HPE
+2.75%
$21.08
SRM
+53.27%
$10.30
MSFT
+0.39%
$474.00
RIG
+3.34%
$4.02
ACHR
+3.62%
$7.44
MU
+7.98%
$223.93
PLTD
-4.69%
$7.31
GPUS
+12.38%
$0.28
AMCR
+1.67%
$8.50
NOK
+2.52%
$6.09
HOOD
+7.14%
$114.97
ORCL
+0.76%
$200.28
CRWV
+2.72%
$73.60
SLB
-1.32%
$35.71
OSRH
+15.48%
$0.64
QBTS
+13.22%
$23.11
DFLI
+4.90%
$0.78
VIVK
+10.13%
$0.14
WLGS
-5.57%
$0.04
MTSR
-0.35%
$70.50
ATON
-6.16%
$2.74
BMNU
+39.92%
$7.36
SMCI
+3.51%
$33.32
FLEX
+3.00%
$56.95
APLD
+12.80%
$23.79
WFC
+1.86%
$84.66
MRK
+2.70%
$100.40
CSCO
+0.18%
$76.24
BURU
+3.03%
$0.21
CAN
+5.55%
$0.96
HBAN
+0.18%
$15.91
AMZE
+21.15%
$0.30
VINE
+21.15%
$0.30
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.